Laura Navarro

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study

A. Belenguer, S. Gil-Perotín, B. Casanova, 2022, Journal of Neurology.

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

B. Casanova, I. Boscá, M. Simó, 2011, Journal of Neurology.

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study

A. Belenguer, S. Gil-Perotín, B. Casanova, 2022, Journal of Neurology.

Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis

X. Montalban, J. Clarimón, A. Lleó, 2018, Multiple sclerosis.

Lipid‐specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

X. Montalban, A. Bar-Or, M. Tintoré, 2015, Annals of neurology.

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

X. Montalban, F. Paul, D. Galimberti, 2020, Frontiers in Neurology.